Tracy M. Downs, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Downs is a urologic surgeon and fellowship-trained specialist in urologic oncology. He performs specialized surgery for complex cancers of the genitourinary tract, including robotic cystectomy and other minimally invasive procedures. He has a special interest in the treatment of bladder cancer, and directs the UW Bladder Cancer and Intravescial Therapy Programs.
UW School of Medicine and Public Health
|Department of Urology|
Professional Certifications and Education
Urologic Oncology, University of California-San Francisco, San Francisco, CA, 2003
Brigham and Women's Hospital, Boston, MA
University of California, San Diego School of Medicine, La Jolla, CA, 1993
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Downs has a joint appointment with the UW Carbone Cancer Center where his translational research focuses on discovery of molecular and urinary biomarkers for bladder cancer and his clinical research focuses on developing new therapies for genitourinary cancers.
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ .
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma; a Novel 3-Dimensional Volumetric Analysis. Urology. 2016 Sep 22;
[PubMed ID: 27667156]
Lane GI Downs TM Soubra A Rao A Hemsley L Laylan C Shi F Konety B .
Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma. J Urol. 2016 Sep 21;
[PubMed ID: 27664580]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ .
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep;118(3):399-407
[PubMed ID: 26589741]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ .
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology. 2016 Jun 23;
[PubMed ID: 27339026]
Downs TM .
Editorial Comment. J Urol. 2016 Feb;195(2):412
[PubMed ID: 26592567]
Blute ML Jr Rushmer TJ Shi F Fuller BJ Abel EJ Jarrard DF Downs TM .
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2015 Nov;194(5):1214-9
[PubMed ID: 26173101]
Abel EJ Heckman JE Hinshaw L Best S Lubner M Jarrard DF Downs TM Nakada SY Lee FT Jr Huang W Ziemlewicz T .
Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. J Urol. 2015 Oct;194(4):886-91
[PubMed ID: 25837535]
Blute ML Jr Abel EJ Downs TM Kelcz F Jarrard DF .
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015 Aug;12(8):435-44
[PubMed ID: 26171803]
Potretzke AM Wong KS Shi F Christensen W Downs TM Abel EJ .
Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann. 2015 Jul-Sep;7(3):355-60
[PubMed ID: 26229325]
Downs TM .
Reducing readmissions and mortality after radical cystectomy. J Urol. 2015 May;193(5):1461-2
[PubMed ID: 25711198]
Downs T .
Editorial comment. J Urol. 2015 Feb;193(2):450
[PubMed ID: 25534588]
Abel EJ Linder BJ Bauman TM Bauer RM Thompson RH Thapa P Devon ON Tarrell RF Frank I Jarrard DF Downs TM Boorjian SA .
Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014 Dec;66(6):1139-47
[PubMed ID: 25194909]
Daneshmand S Schuckman AK Bochner BH Cookson MS Downs TM Gomella LG Grossman HB Kamat AM Konety BR Lee CT Pohar KS Pruthi RS Resnick MJ Smith ND Witjes JA Schoenberg MP Steinberg GD .
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct;11(10):589-96
[PubMed ID: 25245244]
Potretzke A Hillman L Wong K Shi F Brower R Mai S Cetnar JP Abel EJ Downs TM .
NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urol Oncol. 2014 Jul;32(5):631-6
[PubMed ID: 24629498]
Downs TM .
Reply: To PMID 24751188. Urology. 2014 Jun;83(6):1216
[PubMed ID: 24751190]
Downs TM Rayford W Davis DE Nakada SY .
Richard Francis Jones--opening doors and diversifying the urologic workforce: a pioneer in the training of African urologic surgeons in North America. Urology. 2014 Jun;83(6):1213-6
[PubMed ID: 24751189]
Abel EJ Bauman TM Weiker M Shi F Downs TM Jarrard DF Huang W .
Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum Pathol. 2014 May;45(5):1092-9
[PubMed ID: 24746216]
Abel EJ Wong K Sado M Leverson GE Patel SR Downs TM Jarrard DF .
Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014 Apr-Jun;18(2):282-7
[PubMed ID: 24960494]
Shapiro DD Potretzke A Downs TM .
Leukemoid reaction: a rare paraneoplastic syndrome in bladder cancer associated with a grave prognosis. Urology. 2014 Feb;83(2):274-7
[PubMed ID: 24044914]
Truong M Slezak JA Lin CP Iremashvili V Sado M Razmaria AA Leverson G Soloway MS Eggener SE Abel EJ Downs TM Jarrard DF .
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15;119(22):3992-4002
[PubMed ID: 24006289]